This suggests that stabilin-1 potentially plays an adverse role in malignancy by potentiating the suppression of the host immune response to a neoplasm; consequently, a Phase I/II trial, TIETALC, (Tumor Immunity Enabling Technology Against Liver Cancer) is currently being designed at the University of Birmingham to test the efficacy of targeting stabilin-1 in HCC (234). Here, STAB1 is linked to hepatocellular carcinoma.